Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903695 · ClinicalTrials.gov registry record · Phase 2
MemoryXL Effects on Mild Cognitive Impairment Patients
A Phase 2 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00903695 is a Phase 2 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 10 participants.
The verdict
NCT00903695, a Phase 2 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
A vitamin nutriceutical, Memory XL, has been shown to provide maintenance of cognitive status in mild, moderate, and severe Alzheimer's disease patients (2 publications by T. Shea). Because this nutriceutical is now patented by the Univ. of Mass., other trials at that institution may be considered a conflict of interest. Therefore, a study of its effects on Mild Cognitive Impairment (MCI) patients will be conducted by PI who is not affiliated with Univ. of Mass. or with Dr. Shea. The study hypothesis is: Memory XL will maintain or improve the cognitive and behavioral status of patients diagnosed with MCI during the year of participation in the study; normally, 10-25% of MCI patients convert to mild Alzheimer's dementia each year.
Interventions
- DRUG placebo
- DRUG Memory XL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903695
The ClinicalTrials.gov registry entry for NCT00903695 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00903695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00903695 about?
NCT00903695 is a clinical study titled "MemoryXL Effects on Mild Cognitive Impairment Patients". A vitamin nutriceutical, Memory XL, has been shown to provide maintenance of cognitive status in mild, moderate, and severe Alzheimer's disease patients (2 publications by T. Shea). Because this nutriceutical is now patented by the Univ. of Mass., other trials at that institution may be considered a...
What is the current status of trial NCT00903695?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00903695?
The interventions under investigation include: placebo (DRUG), Memory XL (DRUG).
Who is sponsoring clinical trial NCT00903695?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.